Noninvasive programmed stimulation in the setting of ventricular tachycardia catheter ablation.
cardiovascular implantable electronic device
catheter ablation
noninvasive programmed stimulation
outcomes
ventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
30
03
2020
revised:
17
04
2020
accepted:
21
04
2020
pubmed:
25
4
2020
medline:
29
7
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
In the setting of catheter ablation of ventricular tachycardia (VT), invasive programmed ventricular stimulation (PVS) is considered an important tool to assess the (residual) inducibility of ventricular arrhythmias and determine the acute success of the procedure. In patients with cardiovascular implantable electronic devices, noninvasive programmed stimulation via implantable cardioverter-defibrillator (ICD) leads can be an alternative to the invasive PVS with intracardiac catheters. The advantages of noninvasive programmed stimulation include preprocedure planning of the electrophysiology procedure to ensure optimal conditions for successful catheter ablation of VT. Following the procedure, noninvasive programmed stimulation has been shown to be used as a guide for repeat early ablation, to offer better programming of ICD, to offer prognostic value regarding the VT recurrence, and to guide antiarrhythmic drug therapy. The noninvasive nature of noninvasive programmed stimulation makes it an attractive alternative to PVS in patients with ICD who have not undergone catheter ablation of VT to obtain prognostic value regarding the occurrence of VT.
Substances chimiques
Anti-Arrhythmia Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1828-1835Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Europace, 2019(21):1143-1144.
Natale A, Raviele A, Al-Ahmad A, et al. Venice Chart International Consensus document on ventricular tachycardia/ventricular fibrillation ablation. J Cardiovasc Electrophysiol. 2010;21:339-379.
Klemm HU, Ventura R, Steven D, et al. Catheter ablation of multiple ventricular tachycardias after myocardial infarction guided by combined contact and noncontact mapping. Circulation. 2007;115:2697-2704.
Della Bella P, De Ponti R, Uriarte JA, et al. Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia; long-term outcome in relation to acute electrophysiological findings. Eur Heart J. 2002;23:414-424.
Miles WM, Prystowsky EN, Heger JJ, Zipes DP. The implantable transvenous cardioverter: long-term efficacy and reproducible induction of ventricular tachycardia. Circulation. 1986;74:518-524.
Kleiman RB, Callans DJ, Hook BG, Marchlinski FE. Effectiveness of noninvasive stimulation for initiating ventricular tachyarrhythmias in patients with third-generation implantable cardioverter defibrillators. Pacin Clin Electrophysiol. 1994;17:1462-1468.
Costeas XF, Link MS, Foote CB, Homoud MK, Wang PJ, Estes NA. Predictors of ventricular tachycardia recurrence in 100 patients receiving tiered therapy defibrillators. Clin Cardiol. 2000;23:852-856.
Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: a DEFINITE substudy. Pacing Clin Electrophysiol. 2009;32:755-761.
Futyma P, Sander J, Gluszczyk R, Maciolek M, Futyma M, Kulakowski P. Prognostic value of noninvasive programmed stimulation in patients with implantable cardioverter defibrillator. Pacing Clin Electrophysiol. 2018;41:1643-1651.
Oloriz T, Baratto F, Trevisi N, et al. Defining the outcome of ventricular tachycardia ablation: timing and value of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2018;11:e005602. https://doi.org/10.1161/CIRCEP.117.005602
Frankel DS, Mountantonakis SE, Zado ES, et al. Noninvasive programmed ventricular stimulation early after ventricular tachycardia ablation to predict risk of late recurrence. J Am Coll Cardiol. 2012;59:1529-1535.
Shirai Y, Liang JJ, Santangeli P, et al. Long-term outcome and mode of recurrence following noninducibility during noninvasive programmed stimulation after ventricular tachycardia ablation. Pacing Clin Electrophysiol. 2019;42:333-340.
Muser D, Hayashi T, Castro SA, et al. Noninvasive programmed ventricular stimulation-guided management following ventricular tachycardia ablation. JACC Clin Electrophysiol. 2019;5:719-727.
Tung R, Vaseghi M, Frankel DS, et al. Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: an International VT Ablation Center Collaborative Group study. Heart Rhythm. 2015;12:1997-2007.
Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the Sudden Cardiac Death in Heart Failure Trial. Circulation. 2009;120:2170-2176.
Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225-237.
Liang JJ, Yang W, Santangeli P, et al. Amiodarone discontinuation or dose reduction following catheter ablation of ventricular tachycardia in structural heart disease. JACC Clin Electrophysiol. 2017;3:502-511.
Goldschlager N, Epstein AE, Naccarelli GV, et al. Practice Guidelines Sub-committee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone. Heart Rhythm. 2007;4:1250-1259.
Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J. 1985;109:975-983.
Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillators Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329-1338.
Kadish A, Dyer A, Daubert JP, et al. Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151-2158.
Bourier F, Martin R, Martin CA, et al. Is it feasible to offer ‘targeted ablation’ of ventricular tachycardia circuits with better understanding of isthmus anatomy and conduction characteristics? Europace. 2019;21:i27-i33.
Hooks DA, Berte B, Yamashita S, et al. New strategies for ventricular tachycardia and ventricular fibrillation ablation. Expert Rev Cardiovasc Ther. 2005;13:263-276.
Fogoros RN, Elson JJ, Bonnett CA, Fiedler SB, Chenarides JG. Reproducibility of successful drug trials in patients with inducible sustained ventricular tachycardia. Pacing Clin Electrophysiol. 1992;15:295-303.
Rosenbaum MS, Wilber DJ, Finkelstein D, Ruskin JN, Garan H. Immediate reproducibility of electrically induced sustained monomorphic ventricular tachycardia before and during antiarrhythmic therapy. J Am Coll Cardiol. 1991;17:133-138.
Kudenchuk PJ, Kron J, Walance CG, Cutler JE, Griffith KK, McAnulty JH. Day-to-day reproducibility of antiarrhythmic drug trials using programmed extrastimulus techniques for ventricular tachyarrhythmias associated with coronary artery disease. Am J Cardiol. 1990;66:725-730.
McPherson CA, Rosenfeld LE, Batsford WP. Day-to-day reproducibility of responses to right ventricular programmed electrical stimulation: implications for serial drug testing. Am J Cardiol. 1985;55:689-695.
Ferrick KJ, Luce J, Miller S, et al. Reproducibility of electrophysiologic testing during antiarrhythmic therapy for ventricular arrhythmias secondary to coronary disease. Am J Cardiol. 1992;69:1296-1299.
Hief C, Borggrefe M, Chen X, et al. Effects of enflurane on inducibility of ventricular tachycardia. Am J Cardiol. 1991;68:609-613.
Kanaya N, Hirata N, Kurosawa S, Nakayama M, Namiki A. Differential effects of propofol and sevoflurane on heart rate variability. Anesthesiology. 2003;98:34-40.
Li Q, Guan L, Jiang J. Effect of general and epidural anesthesia on autonomic nervous system. Beijing Da Xue Xue Bao Yi Xue Ban. 2003;35:191-194.
Nath S, DiMarco JP, Haines DE. Basic aspects of radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 1994;5:863-876.
Chen SA, Chiang CE, Tai CT, et al. Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures in a tertiary referral center. Am J Cardiol. 1996;77:41-46.
Belhassen B, Shapira I, Sheps D, Laniado S. Programmed ventricular stimulation using up to two extrastimuli and repetition of double extrastimulation for induction of ventricular tachycardia: a new highly sensitive and specific protocol. Am J Cardiol. 1990;65:615-622.
Lin HT, Mann DE, Luck JC, Krafchek J, Magro Sam Sakun V, Wyndham CR. Prospective comparison of right and left ventricular stimulation for induction of sustained ventricular tachycardia. Am J Cardiol. 1987;59:559-563.